Rhythm Pharmaceuticals (RYTM) Financial Statements & Analysis

Rhythm Pharmaceuticals (RYTM) Income Statement

Rhythm Pharmaceuticals reported revenue of $189.76M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 45.8% from $130.13M a year earlier. Rhythm Pharmaceuticals posted a net loss of $201.92M, compared with a net loss of $260.60M a year earlier. Gross margin was 89.7% and operating margin -101.2%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $71.25M, up 46.9% from the same quarter a year earlier.

Rhythm Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Rhythm Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	189.76	130.13	77.43	23.64	3.15	0.00	0.00	0.00	0.00
Cost of Revenue	19.49	13.37	9.30	2.13	0.60	0.69	0.83	0.44	0.22
Gross Profit	170.27	116.76	68.13	21.51	2.56	-0.69	-0.83	-0.44	-0.22
Operating Expenses
Research & Development	167.34	237.96	134.95	108.63	104.13	90.45	109.45	50.34	22.89
Selling, General & Administrative	194.94	144.30	117.53	92.03	68.49	46.13	36.55	28.08	9.52
Operating Expenses	362.28	382.26	252.48	200.66	172.61	135.89	145.17	78.42	32.41
Operating Income	-192.02	-265.50	-184.36	-179.16	-170.06	-136.58	-146.00	-78.42	-32.41
Other Income/Expense
Interest Income	15.29	14.71	13.95	4.03	0.45	2.58	5.27	4.35	0.57
Interest Expense	20.58	20.60	13.89	-5.20	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	-4.03	5.25	0.19	-1.96	100.45	2.58	5.27	4.35	-1.30
Income
Income Before Tax	-196.04	-260.26	-184.11	-181.12	-69.61	-134.00	-140.73	-74.06	-33.71
Income Tax Expense	0.50	0.35	0.56	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-201.92	-260.60	-184.68	-181.12	-69.61	-130.73	-134.62	-74.06	-33.71
Net Income - Continuous Operations	-196.54	-260.60	-184.68	-181.12	-69.61	-130.73	-134.62	-74.06	-33.71
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-190.68	-238.09	-168.46	-177.49	-168.90	-135.89	-145.17	-77.98	-32.19
EBIT	-192.02	-173.10	-170.22	-179.16	-170.06	-136.58	-	-	-
Depreciation & Amortization	1.34	1.56	1.76	1.67	1.16	0.69	0.83	0.44	0.22
Earnings Per Share
Basic EPS	-3.00	-4.00	-3.00	-3.00	-1.00	-3.00	-4.00	-2.00	-1.00
Diluted EPS	-3.00	-4.00	-3.00	-3.00	-1.00	-3.00	-4.00	-2.00	-1.00
Basic Shares Outstanding	64.98	61.00	57.67	52.12	49.60	44.13	36.42	31.00	26.73
Diluted Shares Outstanding	64.98	61.00	57.67	52.12	49.60	44.13	36.42	31.00	26.73

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Rhythm Pharmaceuticals Financial Statements

What was Rhythm Pharmaceuticals's revenue in fiscal 2025?

Rhythm Pharmaceuticals reported revenue of $189.76M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 45.8% from $130.13M a year earlier.

Is Rhythm Pharmaceuticals profitable?

No. Rhythm Pharmaceuticals reported a net loss of $201.92M in fiscal 2025. In fiscal 2024 it lost $260.60M.

What is Rhythm Pharmaceuticals's operating margin?

Rhythm Pharmaceuticals's operating income was −$192.02M on revenue of $189.76M in fiscal 2025, an operating margin of -101.2%, compared with -204.0% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition